Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MME | P08473 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7599136 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL7293707 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL31336702 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL7876545 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| Hydrochloric Acid SCHEMBL28520370 | 0.98 | ALDH1A1 (0.51) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| Phosphoric Acid SCHEMBL28688921 | 0.94 | ACP3 (0.50) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL400880 | 0.90 | ALDH1A1 (0.56) | ALDH1A1MMEKMT2AMEN1MAPT | |
| SCHEMBL4854909 | 0.90 | ALDH1A1 (0.50) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL14017328 | 0.90 | ALDH1A1 (0.50) | ALDH1A1MMESIGMAR1KMT2APOLB | |
| SCHEMBL4855809 | 0.90 | ALDH1A1 (0.50) | ALDH1A1MMESIGMAR1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117986222-A | Biphenyl seven-membered ring compound and preparation method and application thereof | 华侨大学 | 2024-05-07 | — | — | CN | claimed |
| CN-117986222-A | Biphenyl seven-membered ring compound and preparation method and application thereof | 华侨大学 | 2024-05-07 | — | — | CN | disclosed |
| EP-3122747-B1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) | 2020-05-20 | — | — | EP | disclosed |
| EP-3122747-B1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | NORTH & SOUTH BROTHER PHARMACY INVESTMENT CO LTD (CN) | 2020-05-20 | — | — | EP | disclosed |
| US-9771358-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-26 | — | — | US | disclosed |
| US-9771358-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-26 | — | — | US | disclosed |
| US-9771358-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-09-26 | — | — | US | disclosed |
| US-20160347746-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-01 | — | — | US | disclosed |
| US-20160347746-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-01 | — | — | US | disclosed |
| US-20160347746-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-01 | — | — | US | disclosed |
| WO-2015144093-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-10-01 | — | — | WO | disclosed |
| EP-2470546-B1 | HEXAHYDROOXAZINOPTERIDINE COMPOUNDS FOR USE AS MTOR INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-07-24 | — | — | EP | disclosed |
| US-8268819-B2 | Hexahydrooxazinopterine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120178924-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-12 | — | — | US | disclosed |
| EP-2470546-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2012-07-04 | — | — | EP | disclosed |
| US-8163755-B2 | Hexahydrooxazinopterine compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| WO-2011025889-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | WO | disclosed |
| US-20110053921-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178924-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | HPRT1, HCCS, NUDT1 | ALDH1A1 2074/4885MME 4050/4885SIGMAR1 1943/4885 |
| US-20110053921-A1 | HEXAHYDROOXAZINOPTERINE COMPOUNDS | MTOR, RICTOR, EIF4EBP1 | ALDH1A1 4123/4885MME 3584/4885SIGMAR1 3515/4885 |
| US-20160347746-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | ALDH1A1 828/4885MME 1788/4885SIGMAR1 4738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.